Pharma, Inc. Inozyme Net Worth

What's Pharma Inozyme's mailing address?

Pharma's mailing address filed with the SEC is C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON, MA, 02210.

Insiders trading at Inozyme Pharma

Over the last 4 years, insiders at Inozyme Pharma have traded over 0$ worth of Inozyme Pharma stock and bought 11,149,230 units worth 104,131,475$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of 2,019,505$. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth 130,250$.

What does Inozyme Pharma do?

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Inozyme Pharma executives and stock owners

Inozyme Pharma executives and other stock owners filed with the SEC include:

• Axel Bolte M.B.A., M.Sc.,
  Co-Founder, Pres, CEO & Director
• Axel Bolte,
  Co-Founder, Pres, CEO & Director
• Henric Bjorn Bjarke,
  Sr. VP & COO
• Dr. David Thompson M.A., M.S., Ph.D.,
  Chief Devel. Officer & Member of Scientific Advisory Board
• Gayle Gironda,
  Sr. VP of HR
• Stefan Riley,
  Director of Investor Relations
• Stephen J. DiPalma M.B.A.,
  Interim Chief Financial Officer
• Dr. Kevin B. Johnson M.B.A., Ph.D., MBA.,
  Sr. VP of Regulatory Affairs
• Dr. Pedro Huertas,
  Sr. VP & Chief Medical Officer
• Dr. David Thompson Ph.D.,
  Sr. Advisor
• Tara Greene,
  VP of Quality & Compliance
• Brian Luque,
  Director of Investor Relations
• Dr. Yves Sabbagh,
  Sr. VP & Chief Scientific Officer
• Stephen Basso M.B.A.,
  Sr. VP of Fin.
• Steven J. Jungles,
  Sr. VP & Chief Technical Operations Officer
• Pharmaceuticals, Inc. Alexion,
  10% owner
• Joseph Schlessinger,
  10% owner
• Bio Venture Partners Fund I...,
  
• Capital Partners Iii, Llc L...,
  
• Enterprise Associates 15, L...,
  
• Forest Baskett,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Steven J Jungles,
  SVP, CTO
• Sanjay Subramanian,
  SVP, CFO
• Douglas A Treco,
  CEO
• Martin Edwards,
  
• Sarah M Bhagat,
  
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Capital Management, L.P.Kol...,
  
• Springs Capital Management ...,
  
• Sanofi,
  10% owner
• Holdings A/S Novo,
  10% owner
• Lynne Marie Sullivan,
  
• Reinaldo M Diaz,
  
• Henric Bjorn Bjarke,
  SVP, COO
• Edward T Mathers,
  
• Venture Partners X, L.P.Sof...,
  
• Joshua Makower,
  10% owner
• Stephen Basso,
  SVP Finance (PFO)
• Deborah Wenkert,
  SVP, CMO
• Stephen J. Di Palma,
  Interim CFO
• Pharma, Inc. Inozyme,
  Director
• Axel Bolte,
  
• Matthew Winton,
  COO
• Robert Lorne Hopfner,